Loading…
Loading…
EQUITY / NASDAQ · XNMS
Drugs Made In America Acquisition Corp.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗10.88 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 10.88 USD · Volume 0
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -136,934 USD | -131,919 USD | — |
| Net income | 1,726,897 USD | 2,288,579 USD | -24.54% |
| Cash and cash equivalents | 20,280 USD | — | — |
| Total liabilities | 9,136,624 USD | — | — |
| Total equity | -7,406,216 USD | -7,151,715 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 20,280 USD | — | — | 6,137 USD | — | — | — | — |
| Net incomeIncome statement | 1,726,897 USD | 3,697,356 USD | 1,970,459 USD | — | 5,940,643 USD | 2,184,563 USD | 5,727,685 USD | 2,288,579 USD |
| Operating profitIncome statement | -136,934 USD | -280,235 USD | — | — | -2,816,013 USD | -263,703 USD | -726,547 USD | -131,919 USD |
| Total assetsBalance sheet | 146,903,435 USD | — | — | 239,918,847 USD | 239,918,847 USD | 237,632,428 USD | — | — |
| Total equityBalance sheet | -7,406,216 USD | — | -7,377,282 USD | -7,263,981 USD | -7,263,981 USD | -7,328,415 USD | — | -7,151,715 USD |
| Total liabilitiesBalance sheet | 9,136,624 USD | — | — | 7,276,172 USD | 7,276,172 USD | 7,356,611 USD | — | — |
| Financing cash flowCash flow statement | — | -98,361,220 USD | — | — | 231,693,973 USD | — | 231,563,373 USD | — |
| Investing cash flowCash flow statement | — | 98,711,220 USD | — | — | -231,150,000 USD | — | -231,150,000 USD | — |
| Operating cash flowCash flow statement | — | -335,857 USD | — | — | -539,187 USD | — | -414,007 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 04/15/2026 | Open report ↗ Published: 11/18/2025 | Open report ↗ Published: 11/18/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.